KR20240090616A - 안정한 항-ifnar1 제형 - Google Patents

안정한 항-ifnar1 제형 Download PDF

Info

Publication number
KR20240090616A
KR20240090616A KR1020247016705A KR20247016705A KR20240090616A KR 20240090616 A KR20240090616 A KR 20240090616A KR 1020247016705 A KR1020247016705 A KR 1020247016705A KR 20247016705 A KR20247016705 A KR 20247016705A KR 20240090616 A KR20240090616 A KR 20240090616A
Authority
KR
South Korea
Prior art keywords
antibody
formulation
lysine
months
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016705A
Other languages
English (en)
Korean (ko)
Inventor
로버토 데파즈
나탈리 데지저스
재레드 비
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240090616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240090616A publication Critical patent/KR20240090616A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
KR1020247016705A 2015-08-19 2016-08-18 안정한 항-ifnar1 제형 Pending KR20240090616A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
US62/207,164 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation
KR1020207029325A KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029325A Division KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형

Publications (1)

Publication Number Publication Date
KR20240090616A true KR20240090616A (ko) 2024-06-21

Family

ID=58052002

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247016705A Pending KR20240090616A (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형
KR1020227031079A Ceased KR20220127378A (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형
KR1020207029325A Active KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형
KR1020187007314A Active KR102168005B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227031079A Ceased KR20220127378A (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형
KR1020207029325A Active KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형
KR1020187007314A Active KR102168005B1 (ko) 2015-08-19 2016-08-18 안정한 항-ifnar1 제형

Country Status (23)

Country Link
US (1) US10125195B2 (cg-RX-API-DMAC7.html)
EP (3) EP3337502B1 (cg-RX-API-DMAC7.html)
JP (4) JP6720293B2 (cg-RX-API-DMAC7.html)
KR (4) KR20240090616A (cg-RX-API-DMAC7.html)
CN (2) CN122424321A (cg-RX-API-DMAC7.html)
AU (3) AU2016308262C1 (cg-RX-API-DMAC7.html)
CA (1) CA2995222C (cg-RX-API-DMAC7.html)
CY (2) CY1123657T1 (cg-RX-API-DMAC7.html)
DK (2) DK3769781T5 (cg-RX-API-DMAC7.html)
ES (2) ES2818229T3 (cg-RX-API-DMAC7.html)
FI (1) FI3769781T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20201297T1 (cg-RX-API-DMAC7.html)
HU (2) HUE061985T2 (cg-RX-API-DMAC7.html)
IL (1) IL257279B2 (cg-RX-API-DMAC7.html)
LT (2) LT3337502T (cg-RX-API-DMAC7.html)
PL (2) PL3337502T3 (cg-RX-API-DMAC7.html)
PT (2) PT3769781T (cg-RX-API-DMAC7.html)
RS (2) RS60773B1 (cg-RX-API-DMAC7.html)
RU (1) RU2731737C2 (cg-RX-API-DMAC7.html)
SG (1) SG10202106970XA (cg-RX-API-DMAC7.html)
SI (2) SI3769781T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000483T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017031288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
DK4058060T3 (da) * 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
JP2023527054A (ja) * 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ I型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
TWI916375B (zh) 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗il5r抗体製剤
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
AU2022260544A1 (en) 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
TW202317617A (zh) 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
CA3219401A1 (en) 2021-05-12 2022-11-17 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
AU2022317215A1 (en) 2021-07-27 2024-02-29 Astrazeneca Ab Treatment of lupus
EP4412641A2 (en) 2021-10-04 2024-08-14 Astrazeneca AB Treatment of lupus
WO2023073469A1 (en) * 2021-10-29 2023-05-04 Intas Pharmaceuticals Ltd. STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2024009205A1 (en) * 2022-07-06 2024-01-11 Intas Pharmaceuticals Ltd. STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
US20260125482A1 (en) 2022-10-13 2026-05-07 Astrazeneca Ab Treatment of lupus
EP4713361A1 (en) 2023-05-19 2026-03-25 AstraZeneca AB Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease
CA3251574A1 (en) * 2024-08-12 2026-03-01 1000887608 Ontario Inc. Anti-cancer polypeptides, nucleic acid constructs and methods of using same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5731623A (en) * 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
AU2008269086B2 (en) * 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
WO2010056804A1 (en) * 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
MX2014003993A (es) * 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
US10259842B2 (en) * 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3062814A1 (en) 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
CN106604744A (zh) 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス,インコーポレーテッド アグリコシル化治療用抗体の製剤
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1

Also Published As

Publication number Publication date
SI3769781T1 (sl) 2023-06-30
AU2020203306B2 (en) 2021-09-09
IL257279A (en) 2018-03-29
JP2022066345A (ja) 2022-04-28
US10125195B2 (en) 2018-11-13
CY1123657T1 (el) 2022-03-24
KR102168005B1 (ko) 2020-10-21
SI3337502T1 (sl) 2020-10-30
RU2731737C2 (ru) 2020-09-08
HRP20230463T1 (hr) 2023-07-21
HUE061985T2 (hu) 2023-09-28
EP3337502A1 (en) 2018-06-27
ES2818229T3 (es) 2021-04-09
DK3769781T3 (da) 2023-06-19
HUE051862T2 (hu) 2021-03-29
LT3337502T (lt) 2020-09-25
AU2020203306C1 (en) 2022-03-31
EP4233892A3 (en) 2023-10-25
IL257279B2 (en) 2023-04-01
KR20220127378A (ko) 2022-09-19
DK3769781T5 (da) 2024-08-19
SMT202000483T1 (it) 2020-11-10
JP2024161043A (ja) 2024-11-15
AU2016308262B2 (en) 2020-04-30
AU2016308262A1 (en) 2018-03-08
KR20180041173A (ko) 2018-04-23
LT3769781T (lt) 2023-06-12
US20170051066A1 (en) 2017-02-23
WO2017031288A1 (en) 2017-02-23
BR112018002196A2 (pt) 2019-04-30
RU2018107725A (ru) 2019-09-19
CA2995222A1 (en) 2017-02-23
PT3337502T (pt) 2020-09-23
EP4233892A2 (en) 2023-08-30
BR112018002196A8 (pt) 2021-05-04
JP6720293B2 (ja) 2020-07-08
CY1126062T1 (el) 2023-11-15
EP3769781B1 (en) 2023-04-19
SG10202106970XA (en) 2021-07-29
CA2995222C (en) 2021-07-13
AU2021257915A1 (en) 2021-11-18
KR20200119916A (ko) 2020-10-20
IL257279B (en) 2022-12-01
PL3769781T3 (pl) 2023-07-17
RS64263B1 (sr) 2023-07-31
EP3337502A4 (en) 2019-01-23
JP2018523676A (ja) 2018-08-23
RS60773B1 (sr) 2020-10-30
RU2018107725A3 (cg-RX-API-DMAC7.html) 2019-10-02
CN107921109A (zh) 2018-04-17
EP3337502B1 (en) 2020-06-24
HRP20201297T1 (hr) 2020-11-27
PL3337502T3 (pl) 2021-01-11
SMT202300176T1 (it) 2023-07-20
JP2020158527A (ja) 2020-10-01
EP3769781A1 (en) 2021-01-27
DK3337502T3 (da) 2020-09-14
PT3769781T (pt) 2023-06-19
CN122424321A (zh) 2026-07-21
ES2947488T3 (es) 2023-08-10
KR102669174B1 (ko) 2024-06-10
AU2016308262C1 (en) 2022-04-21
CN107921109B (zh) 2026-04-14
AU2020203306A1 (en) 2020-06-11
JP7035119B2 (ja) 2022-03-14
FI3769781T3 (fi) 2023-06-07
HK1256195A1 (en) 2019-09-13

Similar Documents

Publication Publication Date Title
KR102669174B1 (ko) 안정한 항-ifnar1 제형
EP3060229B1 (en) Stable, aqueous antibody formulations
ES2813398T3 (es) Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
HK40098575A (en) Stable anti-ifnar1 formulation
HK40045114B (en) Stable anti-ifnar1 formulation
HK40045114A (en) Stable anti-ifnar1 formulation
HK1256195B (en) Stable anti-ifnar1 formulation
BR112018002196B1 (pt) Formulação de anticorpo, recipiente selado, forma farmacêutica de dosagem unitária apropriada para administração parenteral a um ser humano e uso

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240520

Application number text: 1020207029325

Filing date: 20201013

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240618

Comment text: Request for Examination of Application

PG1501 Laying open of application